Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Flortaucipir F 18 - Avid Radiopharmaceuticals

Next Previous
X
Search
Drug Profile

Flortaucipir F 18 - Avid Radiopharmaceuticals

Alternative Names: 18F-AV-1451; [18F]-T-807; [3H]AV 1451; [F-18]T807; [F18]AV1451; Fluorine 18 AV 1451; LY3191748; T807; Tauvid

Latest Information Update: 29 Jul 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Siemens Medical Solutions
  • Developer Avid Radiopharmaceuticals; First Affiliated Hospital of Fujian Medical University; Northwestern University
  • Class Fluorine compounds; Imaging agents; Indoles; Pyridines; Pyridones; Radiopharmaceutical diagnostics; Small molecules
  • Mechanism of Action Diagnostic imaging enhancers; Positron-emission tomography enhancers
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity No

Highest Development Phases

  • Marketed Alzheimer's disease
  • Phase II Brain injuries; Cognition disorders; Dementia; Depressive disorders; Neurodegenerative disorders; Progressive supranuclear palsy
  • No development reported Aphasia; Mild cognitive impairment

Most Recent Events

  • 29 Jul 2024 Avid Radiopharmaceuticals and Skåne University Hospital completes a phase II trial for Cognition disorders, Neurodegenerative disorders, Dementia and Alzheimer's disease (Diagnosis) in Sweden (IV), prior to July 2024 (EudraCT2014-000422-38)
  • 28 Jul 2024 No recent reports of development identified for phase-I development in Neurodegenerative-disorders(Diagnosis) in China (IV, Injection)
  • 16 Jul 2023 Efficacy data from a phase II/III trial in Alzheimer's Disease presented at the Alzheimer's Association International Conference 2023 (AAIC-2023)

You need to be a logged in or subscribed to view this content Request demo

If your organization or you do not have a subscription, try one of the following:
  • Contacting your organization’s admin about adding this content to your AdisInsight subscription
  • Buying a PDF version of any individual profile
  • Request a free trial
If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top